「the 20」の検索結果
144件：106～110件目を表示
-
g approval in Japan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 anta...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf -
g approval in Japan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 anta...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222_0.pdf -
临床试验信息 | 研究与开发 | 千寿制药株式会社
clinical trials sponsored by SENJU PHARMACEUTICAL Co., Ltd. (hereinafter referred to as “SENJU”) to the public including patients and their families, in order to ensure the transparency of clinical tr...
http://www.senju.co.jp/chinese/rd/trial.html -
y, President: Shuhei Yoshida) announced today that it has obtained approval for a partial change in the marketing authorization of “Aibeta® Combination Eye Drops” (generic name: brimonidine tartrate a...
https://www.senju.co.jp/system/files/content_news/2025-09/ENG_20250904_0.pdf -
y, President: Shuhei Yoshida) announced today that it has obtained approval for a partial change in the marketing authorization of “Aibeta® Combination Eye Drops” (generic name: brimonidine tartrate a...
https://www.senju.co.jp/system/files/content_news/2025-09/ENG_20250904.pdf